roxadustat

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Hemodialysis Patients With Renal Anemia

Conditions

Hemodialysis Patients With Renal Anemia

Trial Timeline

May 16, 2016 → Nov 28, 2017

NCT ID

NCT02779764

About roxadustat

roxadustat is a phase 3 stage product being developed by Astellas Pharma for Hemodialysis Patients With Renal Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02779764. Target conditions include Hemodialysis Patients With Renal Anemia.

What happened to similar drugs?

2 of 15 similar drugs in Hemodialysis Patients With Renal Anemia were approved

Approved (2) Terminated (0) Active (13)

🔄R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placeboChugai PharmaceuticalPhase 3

🔄R744 + R744Chugai PharmaceuticalPhase 3

🔄R744Chugai PharmaceuticalPhase 3

🔄roxadustat + Darbepoetin alfaAstellas PharmaPhase 3

🔄roxadustatAstellas PharmaPhase 3

✅DoravirineMerckApproved

🔄PA21 + Sevelamer hydrochlorideKissei PharmaceuticalPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (12)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05970172	Phase 3	Recruiting	Jan 16, 2024	Oct 30, 2027	Chronic Kidney Disease
NCT04408820	Pre-clinical	Completed	Jun 1, 2020	Jun 23, 2025	Renal Anemia
NCT04076943	Phase 2	Completed	Aug 20, 2019	Apr 23, 2021	Chemotherapy Induced Anemia
NCT03960489	Phase 1	Completed	Jul 31, 2019	Oct 14, 2019	Healthy Adult Subjects
NCT02964936	Phase 3	Completed	Jan 11, 2017	Aug 15, 2018	Chronic Kidney Disease
NCT02965040	Phase 1	Completed	Dec 12, 2016	Dec 11, 2017	Normal Renal Function
NCT02780726	Phase 3	Completed	Jun 22, 2016	Aug 2, 2017	Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia
NCT02780141	Phase 3	Completed	Jun 2, 2016	Dec 12, 2017	ESA-naive Hemodialysis Chronic Kidney Disease Patients With Anemia
NCT02779764	Phase 3	Completed	May 16, 2016	Nov 28, 2017	Hemodialysis Patients With Renal Anemia
NCT01630889	Phase 2	Completed	May 18, 2012	Dec 12, 2019	Chronic Kidney Disease
NCT01244763	Phase 2	Completed	Oct 29, 2010	Jun 13, 2012	Chronic Kidney Disease
NCT01083888	Phase 1	Completed	Feb 15, 2010	Jun 7, 2010	Anemia

Competing Products

20 competing products in Hemodialysis Patients With Renal Anemia

See all competitors

Product	Company	Stage	Hype Score
R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placebo	Chugai Pharmaceutical	Phase 3	40
R744 + R744	Chugai Pharmaceutical	Phase 3	40
R744	Chugai Pharmaceutical	Phase 3	40
ASP7991	Astellas Pharma	Phase 1	29
roxadustat + Darbepoetin alfa	Astellas Pharma	Phase 3	40
roxadustat	Astellas Pharma	Phase 3	40
ASP1585	Astellas Pharma	Phase 2	35
Kiklin capsules	Astellas Pharma	Pre-clinical	26
Doravirine	Merck	Approved	43
BPS804 + Placebo	Novartis	Phase 2	27
PA21 + Sevelamer hydrochloride	Kissei Pharmaceutical	Phase 3	40
PA21 + PA21 + PA21 + PA21 + Placebo	Kissei Pharmaceutical	Phase 2	35
PA21	Kissei Pharmaceutical	Phase 3	40
PA21	Kissei Pharmaceutical	Phase 3	40
[¹⁴C]Etelcalcetide	Amgen	Phase 1	29
Epoetin Hospira	Pfizer	Phase 3	40
Epoetin Hospira	Pfizer	Phase 3	40
sodium thiosulfate	Sanofi	Pre-clinical	26
Enoxaparine	Sanofi	Approved	43
Alirocumab 150 MG/ML [Praluent]	Regeneron Pharmaceuticals	Phase 3	36